Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
about
Drug Hypersensitivity and Desensitizations: Mechanisms and New ApproachesManagement of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendationsHypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.Ceftaroline desensitization procedure in a pregnant patient with multiple drug allergies.Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer.Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.Antibiotics Are the Most Commonly Identified Cause of Perioperative Hypersensitivity ReactionsImmune-mediated reactions to vancomycin: A systematic case review and analysisOutcomes and safety of rapid desensitization for chemotherapy hypersensitivity.Increasing the chances for platinum-sensitive ovarian cancer patients.Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes.Evaluation and management of hypersensitivity reactions to chemotherapy agents.Platinum hypersensitivity and desensitization.Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization.Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations.Platinum or nonplatinum in recurrent ovarian cancer: that is the question.Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy.
P2860
Q33839145-614C774F-ACF1-4F11-9A58-ADB431AEAC8BQ33982751-D4028024-6216-4F41-81C9-BD4A505DBF14Q34155719-3D522FA5-9B2C-40E4-959C-BA0DD4522A11Q35205223-88E4E82A-5402-426C-B3B0-F7CC53419A42Q35628320-D889D433-7352-4FB1-92D7-8EF8559418F5Q36753922-47FCEA96-3B5F-4521-9AA9-A0D0C40A8E45Q37016053-DBCA0E22-A8C3-4C77-B099-7A2B611944AEQ37080579-03498B3E-ADCF-4D47-A59B-4F70E5D9EF94Q37099007-1CC7531E-B86B-4BD3-B29B-B506F0278EF4Q37650561-73E3E071-1F0B-4A46-94E5-49129B8BEAA3Q38160259-38C888C2-77F7-4D0B-9557-5B06D3B1465BQ38222050-196B68EA-AC6E-47B3-846F-6D0823B3A481Q38226223-17C54FBC-8E11-496D-A931-DCB9BA6E613DQ38347027-12B83DFA-62AD-4736-AEB9-3650CD7551E0Q38521636-130DCF9E-5452-4F76-B552-B728EEE0E4F5Q38541188-211505E3-3DB4-4CDF-A601-4154F99D8246Q39179349-1BB25E2F-C3CE-4826-91E1-360B5A6C107DQ41127404-E851CB25-FA2F-491A-A3D6-4B08BF8AA09BQ44842257-1A77F0C3-C81A-45CE-8918-6ED63D1F6944Q47903289-46724C0F-0AC8-4963-BE5B-79CC78F3775BQ55374006-8BC8F39F-E8DB-4A9D-83B2-46362A778155Q55459950-63A63F6A-2D5A-48C1-B44A-B1A7D7156C26
P2860
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk stratification for desens ...... l presentation and management.
@en
Risk stratification for desens ...... l presentation and management.
@nl
type
label
Risk stratification for desens ...... l presentation and management.
@en
Risk stratification for desens ...... l presentation and management.
@nl
prefLabel
Risk stratification for desens ...... l presentation and management.
@en
Risk stratification for desens ...... l presentation and management.
@nl
P2093
P1476
Risk stratification for desens ...... l presentation and management.
@en
P2093
Aleena Banerji
Carolyn N Krasner
Johnson T Wong
Michael V Seiden
Paul E Hesterberg
Richard T Penson
P304
P356
10.1016/J.JACI.2009.02.042
P407
P577
2009-06-01T00:00:00Z